

Pharma stock jumps after receiving U.S. FDA approval to manufacture HIV treatment tablets

Lupin Limited has received tentative U.S. FDA approval for its HIV treatment tablets, bioequivalent to Gilead's Biktarvy®. The product will be manufactured at Lupin's Nagpur facility for adult and pediatric patients weighing over 25 kg.

The shares of one of the pharmaceutical company, specializing in a broad range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients (APIs), jumped by upto 2 percent upon receiving U.S. FDA Approval for manufacturing HIV Treatment Tablets.

With a market capitalization of Rs. 91,924.13 crores on Thursday, the shares of **Lupin Limited** rose by upto 2.1 percent, making a high of Rs. 2034.95 per share compared to its previous closing price of Rs. 1991.20 per share.

Lupin Limited, engaged in a broad range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, has received tentative approval from the U.S. FDA.

The approval is for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets (50 mg/200 mg/25 mg) used in the treatment of HIV in adults and children weighing at least 25 kg. The product, bioequivalent to Gilead's Biktarvy®, will be manufactured at Lupin's Nagpur facility.

Financilas & Others

The company's revenue rose by 11.93 percent from Rs. 5,600 crore to Rs. 6,268 crore in Q1FY25-26. Meanwhile, Net profit rose from Rs. 806 crore to Rs. 1,221 crore during the same period.

The company has shown strong financial performance with a Return on Capital Employed (ROCE) of 21.3% and Return on Equity (ROE) of 20.6%, indicating efficient use of capital. Its debt-to-equity ratio is low at 0.32, reflecting a healthy balance sheet. The stock P/E is 24.9, which is attractive compared to the industry average of 34.0.

It has delivered an impressive profit growth of 54.9% CAGR over the last 5 years and maintained a consistent dividend payout of 26.0%, highlighting its growth potential.

Lupin Limited, headquartered in Mumbai, is a global pharmaceutical company with a presence in over 100 markets. It offers a wide range of products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds strong positions in India and the U.S. across key therapy areas like respiratory, cardiovascular, anti-diabetic, CNS, and women's health.

With 15 advanced manufacturing facilities, 7 global research centers, and a workforce of over 23,000 professionals, Lupin is dedicated to delivering high-quality healthcare solutions. Through its subsidiaries, Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions, the company continues to focus on improving patient health outcomes worldwide.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

To know more, visit www.lupin.com or follow us on LinkedIn <https://www.linkedin.com/company/lupin>

News Source:

<https://tradebrains.in/pharma-stock-jumps-after-receiving-u-s-fda-approval-to-manufacture-hiv-treatment-tablets>